The case is presented of a 70 year old woman with mild hypercholesterolaemia and hypertension who was readmitted to hospital six months after a previous admission for angina pectoris. The patient was treated with verapamil, nifedipine, and aspirin, and had been receiving bezafibrate (400 mg every 12 hours) for the previous 40 days. Twenty four hours after admission she developed podagra, which was treated with indomethacin (100 mg daily). Eight days after admission myocardial infarction was suspected, and the next day she presented with symptoms of rhabdomyolysis, which was confirmed by laboratory tests. Bezafibrate was withdrawn and the patient became asymptomatic after seven days. It is recommended that doctors should be aware of the possibility of patients, especially those with impaired renal function, developing rhabdomyolysis while being treated with bezafibrate.
These workers suggest that the cellular infiltrate was due to mononuclear elements being present to remove tissue debris. We feel that these histological findings are not sufficient to diagnose polymyositis.7 in the absence of inflammatory infiltrates. We also maintain that the lack of adequate definition in patients with drug induced rhabdomyolysis may lead to conflicting situations with respect to treatment and prognosis.
It is interesting to note that lovastatin induced rhabdomyolysis has been described in association with other drugs such as gemfibrozil,'6 cyclosporin,'8 and erythromycin.'9 Our patient developed acute rhabdomyolysis just after the introduction of indomethacin; this drug has not been involved in drug induced rhabdomyolysis, but it is known that indomethacin can lead to an impairment of renal function in older patients and in this way it may predispose patients to bezafibrate toxicity.
The actual mechanism of this toxic effect by bezafibrate is far from clear; the drug is rapidly absorbed after a dose by mouth, is highly protein bound, and is largely excreted unchanged in urine; therefore a dose reduction is recommended in patients with impaired renal function.' Our patient was receiving a larger dose than normally advised (400 mg daily or less in case of renal failure), but from other reports it seems that even with adjusted doses, the concentrations of bezafibrate in blood were high enough to be toxic. 4 
